Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Novel approaches including gene editing are creeping towards approval.
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.